FIG 6.

Comparison of HIV proviruses in HIV-HBV co-infected and HIV mono-infected participants after 3 years of antiretroviral therapy. (A) Infection frequency of HIV per 10⁶ CD4 T cells from both pre-therapy and on-therapy samples from 6 mono-infected participants, where the frequency of genetically-intact HIV (in green) may also be viewed as a proportion of the total HIV frequency. The red arrow indicates a participant that was still viremic at the on-therapy sampling time point. (B) Change in the infection frequency of HIV proviruses pre-therapy and on-therapy, sequenced from HIV-HBV co-infected participants (blue) and HIV mono-infected participants (yellow). In red is a co-infected individual who was still viremic at the time of on-therapy sampling. Panels C to E exclude this viremic participant. (C) Comparison of the infection frequency of genetically-intact HIV proviruses between co-infected individuals and mono-infected individuals after 3 years of ART. Statistical significance was calculated with a Mann-Whitney test. (D) Change in the proportion of sequences belonging to an expansion of identical sequences (EIS) in co-infected participants (blue) and mono-infected participants (yellow). (E) Change in the infection frequency of HIV proviruses with different defects in pre-therapy (PT) and on-therapy (OT) sequenced from HIV-HBV co-infected participants (blue) and HIV mono-infected participants (yellow). Mixed effects modelling was used to calculate the P-value. The top row shows the comparison of infection frequencies between groups, while the bottom row shows the change over time as paired data.